Results 61 to 70 of about 1,820,241 (196)

Opioid Prescribing Changes in Advanced Cancer Before and After Withdrawal of Hydromorphone Slow‐Release Tablets

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Hydromorphone slow‐release tablet withdrawal from the Australian market altered opioid prescribing patterns in advanced cancer pain. Methadone use increased by nearly 50% and median doses doubled. There may be a need to tailor clinician training on safe and effective use of methadone and other opioids as appropriate. ABSTRACT Aim Ongoing disruptions to
Aaron K. Wong   +7 more
wiley   +1 more source

Receptor Studies in Opioid Receptor and Opioid Peptide Gene Knockout Mice. [PDF]

open access: yes, 2020
1. It is postulated that dynorphin inhibits the cocaine-induced increase in striatal dopamine levels, that may contribute to dynorphin’s ability to prevent cocaine-induced conditioned place preference and to attenuate an increase in locomotor activity ...
Yoo, Ji Hoon.
core  

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

The NOP receptor involvement in both withdrawal- and CCk-8-induced contracture responses of guinea pig isolated ileum after acute activation of κ-opioid receptor

open access: yes, 2012
In isolated guinea-pig ileum (GPI), the κ-opioid acute withdrawal response is under the control of several neuronal signaling systems, including the μ-opioid, the A(1)-adenosine and the CB(1) receptors, which are involved in the inhibitory control ...
TUCCI, PAOLO   +6 more
core   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Peripheral sensitization increases opioid receptor expression and activation by crotalphine in rats.

open access: yesPLoS ONE, 2014
Inflammation enhances the peripheral analgesic efficacy of opioid drugs, but the mechanisms involved in this phenomenon have not been fully elucidated. Crotalphine (CRP), a peptide that was first isolated from South American rattlesnake C.d.
Vanessa Olzon Zambelli   +6 more
doaj   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

The role of the large conductance Ca2+-activated K+ channel in adenosine receptor-mediated cytoprotection [PDF]

open access: yes, 2009
The rat embryonic cardiomyoblast-derived H9c2 cell line is increasingly used for studies into cardioprotection, as these cells display similar properties to primary cardiomyocytes.
Fretwell, Laurice V, Fretwell, LV
core  

Characterization of BU09059: A Novel Potent Selective κ‑Receptor Antagonist

open access: yes, 2015
Kappa-opioid receptor (κ) antagonists are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing κ-antagonists has been limited by the pharmacodynamic properties of prototypic κ-selective antagonists; that is ...
Mary J. Clark (1295067)   +7 more
core   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy